Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3597119 | 0.92 | ALDH1A1 (0.39) | DRD2DRD4ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL3603379 | 0.85 | CRBN (0.36) | DRD2DRD4ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL3595636 | 0.82 | TSHR (0.46) | DRD2DRD4ALDH1A1RAB9ACRBN | |
| SCHEMBL3599952 | 0.81 | ALDH1A1 (0.37) | DRD2DRD4ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL3593849 | 0.81 | DRD2 (0.41) | DRD2DRD4ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL3604098 | 0.81 | DRD2 (0.39) | DRD2DRD4ALDH1A1RAB9ACRBN | |
| SCHEMBL3599720 | 0.81 | DRD2 (0.39) | DRD2DRD4ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL3594128 | 0.80 | POLB (0.39) | DRD2DRD4ALDH1A1RAB9ACRBN | |
| SCHEMBL3607360 | 0.79 | KMT2A (0.37) | DRD2DRD4ALDH1A1RAB9ACRBN | |
| SCHEMBL3595927 | 0.79 | DRD2 (0.37) | DRD2DRD4ALDH1A1RAB9ACRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | DRD2 530/4885DRD4 795/4885ALDH1A1 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.